Tehran University of Medical Sciences

Science Communicator Platform

Share By
The Prospect of Targeting T Cell Immunoglobulin and Mucin-Domain Containing-3 in Renal Cell Carcinoma Immunotherapy Publisher Pubmed



Mohsenzadegan M1 ; Nowroozi MR2 ; Fotovvat A2 ; Bavandpour Baghshahi P3 ; Bokaie S4 ; Inanloo SH2 ; Sharifi L2
Authors

Source: Scandinavian Journal of Immunology Published:2022


Abstract

Despite the advances in the diagnosis and treatment of renal cell carcinoma (RCC), it remains one of the most deadly urological cancers. At present, using immune checkpoint inhibition and their combination with antiangiogenic therapy is the standard of care in patients with advanced RCC. Unfortunately, a considerable part of tumour-bearing hosts does not benefit from this type of treatment. However, our knowledge about the detailed role of mucin-domain containing-3 (TIM-3) in the RCC cells is little, and further studies are required in this field, but its significant expression in the RCC microenvironment makes this receptor a promising target for designing new monoclonal antibodies alone or in combination with other checkpoint inhibitors for RCC immunotherapy. © 2022 The Scandinavian Foundation for Immunology.
Related Docs
View other Related Docs
1. Recent Advances in Immune Checkpoint Therapy in Non-Small Cell Lung Cancer and Opportunities for Nanoparticle-Based Therapy, European Journal of Pharmacology (2021)
2. Combination Therapy With Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges, Resistance Mechanisms, and the Role of Microbiota, Biomedicine and Pharmacotherapy (2025)
3. Immunotherapy in Bladder and Renal Cancers, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (10)
Saeid Amanpour (1)
Other Related Docs
4. Abscopal Effect in Radioimmunotherapy, International Immunopharmacology (2020)
5. Immune Checkpoint Inhibition for Pancreatic Cancer, Acta Medica Iranica (2023)
6. Update on Immune-Based Therapy Strategies Targeting Cancer Stem Cells, Cancer Medicine (2023)
7. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
8. Specific Immunotherapy in Renal Cancer: A Systematic Review, Therapeutic Advances in Urology (2017)
9. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
10. Tumor Immunology, Clinical Immunology (2022)
11. Down-Regulation of Immune Checkpoints by Doxorubicin and Carboplatin-Containing Neoadjuvant Regimens in a Murine Breast Cancer Model, Iranian Journal of Basic Medical Sciences (2021)
12. Immune Checkpoint Inhibitor (Ici) Therapy in Central Nervous System Cancers: State-Of-The-Art and Future Outlook, International Immunopharmacology (2025)
13. The Therapeutic Potential of Targeting Tumor Microenvironment and Modulation of Immunotherapy in Gastrointestinal Cancer, Current Cancer Drug Targets (2025)
14. Contribution of Natural Killer Cells in Innate Immunity Against Colorectal Cancer, Frontiers in Oncology (2023)
15. The Potential Role of Immunotherapy in Wilms’ Tumor: Opportunities and Challenges, Current Pharmaceutical Design (2023)
16. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)
17. Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer: From Immunological Mechanisms to Clinical Evidence, International Immunopharmacology (2021)
18. Immunotherapeutic Targets in Non-Small Cell Lung Cancer, Immunology (2023)
19. Anti-Ctla-4 Nanobody As a Promising Approach in Cancer Immunotherapy, Cell death & disease (2024)